These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1224 related items for PubMed ID: 22186961

  • 1. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [Abstract] [Full Text] [Related]

  • 2. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

  • 3. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 21; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 4. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.
    Thromb Haemost; 2013 Feb 21; 109(2):328-36. PubMed ID: 23179181
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.
    Clin Ther; 2013 Jul 21; 35(7):967-984.e2. PubMed ID: 23870607
    [Abstract] [Full Text] [Related]

  • 7. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep 21; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP, Halperin JL.
    Hosp Pract (1995); 2013 Feb 21; 41(1):37-48. PubMed ID: 23466966
    [Abstract] [Full Text] [Related]

  • 13. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL, Lindsley JP, Moranville MP, Habibi M, Khurram IM, Spragg DD, Berger RD, Calkins H, Marine JE.
    Ann Pharmacother; 2015 Mar 21; 49(3):278-84. PubMed ID: 25515868
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):480-6. PubMed ID: 22787066
    [Abstract] [Full Text] [Related]

  • 15. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY, Kim RB.
    Can J Cardiol; 2013 Jul 01; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [Abstract] [Full Text] [Related]

  • 16. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.
    BMJ; 2015 Apr 24; 350():h1857. PubMed ID: 25910928
    [Abstract] [Full Text] [Related]

  • 17. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS.
    Int Angiol; 2014 Aug 24; 33(4):301-8. PubMed ID: 25056161
    [Abstract] [Full Text] [Related]

  • 18. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F, Spyropoulos AC.
    Hosp Pract (1995); 2013 Feb 24; 41(1):8-18. PubMed ID: 23466963
    [Abstract] [Full Text] [Related]

  • 19. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.
    J Med Econ; 2013 Sep 24; 16(9):1163-8. PubMed ID: 23869941
    [Abstract] [Full Text] [Related]

  • 20. Direct oral anticoagulants in atrial fibrillation.
    Noll G, Noll S, Hürlimann D.
    Semin Hematol; 2014 Apr 24; 51(2):139-46. PubMed ID: 24861798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.